Journal
CLINICAL CANCER RESEARCH
Volume 13, Issue 17, Pages 5144-5149Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-07-0869
Keywords
-
Categories
Funding
- Intramural NIH HHS Funding Source: Medline
Ask authors/readers for more resources
Purpose: To determine the toxicities, maximum tolerated dose (MTD) and pharmacokinetics of the recombinant immunotoxin SS1P (anti-mesothelin dsFv-PE38) in patients with mesothelin-expressing cancers. Experimental Design: SS1P given as a 30-min i.v. infusion every other day (QOD) for six or three doses was administered to 34 patients with advanced mesothelioma (n = 20), ovarian (n = 12), and pancreatic (n = 2) cancer. Results: The initial cohort of 17 patients received SS1P QOD x 6 doses and the MTD was 18 mu g/ kg/dose. Dose-limiting toxicities (DLT) included grade 3 uticaria (one patient) and grade 3 vascular leak syndrome (two patients). To allow further SS1P dose escalation, 17 patients were treated on the QOD x 3 schedule and the MTD was 45 mu g/kg/dose. The DLT was grade 3 pleuritis and was seen in two of two patients treated at a dose of 60 mu g/kg and in one of nine patients treated at a dose of 45 mu g/kg. At the MTD of 45 mu g/kg, the mean C-max Of SS1P was 483 ng/mL and half-life was 466 min. Of the 33 evaluable patients treated, 4 had minor responses, 19 had stable disease (including 2 with resolution of ascites), and 10 had progressive disease. Conclusions: SS1P is well tolerated with pleuritis as the DLT at the highest dose level. Evidence of clinical activity was noted in a group of heavily pretreated patients. Phase 11 clinical trials of SS1P are being planned for malignant mesothelioma and other mesothelin-expressing malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available